Analysis for prognostic factors of 60-day mortality: Evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 10, Issue 4, 2011, Pages 317-324

  Giessen, Clemens ^a   Stintzing, Sebastian ^a   Laubender, Ruediger Paul ^b   Ankerst, Donna Pauler ^c   Schulz, Christoph ^a   Moosmann, Nicolas ^a   Modest, Dominik Paul ^a   Schalhorn, Andreas ^a   Von Weikersthal, Ludwig Fischer ^d   Heinemann, Volker ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d MVZ Gesundheitszentrum St Marien   (Germany)

Author keywords

60 day mortality; Colorectal cancer; First line treatment; Irinotecan; Oxaliplatin; Prognostic factors

Indexed keywords

ALKALINE PHOSPHATASE; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; HEMOGLOBIN; IRINOTECAN; LACTATE DEHYDROGENASE; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CAUSE OF DEATH; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SUICIDE; THROMBOCYTE COUNT; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84855939151     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2011.03.027     Document Type: Article

References (39)

1. O. Katopodis, P. Ross, and A.R. Norman Sixty-day all-cause mortality rates in patients treated for gastrointestinal cancers, in randomised trials, at the Royal Marsden Hospital Eur J Cancer 40 2004 2230 2236 (Pubitemid 39348872)
2. M.L. Rothenberg, N.J. Meropol, and E.A. Poplin Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel J Clin Oncol 19 2001 3801 3807 (Pubitemid 32880058)
3. F. Saliba, R. Hagipantelli, and J.L. Misset Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment J Clin Oncol 16 1998 2745 2751 (Pubitemid 28363040)
4. F. Goldwasser, M. Gross, and J.M. Tigaud CPT-11/Oxaliplatin (L-OHP) Combination Every Two Weeks: Final Results of a Phase I Study in Advanced Digestive Malignancies (Meeting Abstract) Proc Am Soc Clin Oncol 19 suppl 1999 abstract A675
5. E. Wasserman, C. Cuvier, and F. Lokiec Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics J Clin Oncol 17 1999 1751 1759 (Pubitemid 29269244)
6. W. Scheithauer, G.V. Kornek, and M. Raderer Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer J Clin Oncol 17 1999 902 906 (Pubitemid 29109321)
7. Y. Bcouarn, P. Senesse, and S. Thzenas A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Federation Nationale des Centres de Lutte Contre le Cancer Ann Oncol 18 2007 2000 2005 (Pubitemid 350286239)
8. D.G. Haller, M.L. Rothenberg, and A.O. Wong Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma J Clin Oncol 26 2008 4544 4550
9. R.M. Goldberg, D.J. Sargent, and R.F. Morton A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 2004 23 30 (Pubitemid 41095110)
10. E. Bajetta, E. Beretta, and M. De Bartolomeo Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients Oncology 66 2004 132 137 (Pubitemid 38608380)
11. N. Kemeny, W. Tong, and M. Gonen Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer Ann Oncol 13 2002 1490 1496
12. Y. Bcouarn, E. Gamelin, and B. Coudert Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients J Clin Oncol 19 2001 4195 4201 (Pubitemid 33081636)
13. N. Zeghari-Squalli, E. Raymond, and E. Cvitkovic Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin Clin Cancer Res 5 1999 1189 1196 (Pubitemid 29233237)
14. F. Lokiec, E. Wasserman, and E. Cvitkovic Final results of the pharmacokinetic study of both CPT-11 (C) and LOHP (L) in combination durin a phase I trial in gastrointestinal cancer patients (meeting abstract) abstract A778 Proc Am Soc Clin Oncol 18 1998 2688 2695
15. L. Fischer von Weikersthal, A. Schalhorn, and M. Stauch Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer Eur J Cancer 47 2010 206 214
16. B. Chibaudel, C. Tournigand, and F. Bonnetain Handy prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer J Clin Oncol 28 suppl 2010 abstract 3577 www. asco.org Accessed May 1, 2011
17. R. Diaz, J. Aparicio, and R. Girons Analysis of prognostic factors and applicability of Kohne's prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy Clin Colorectal Cancer 5 2005 197 202
18. C.H. Khne, D. Cunningham, and C.F. Di Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients Ann Oncol 13 2002 308 317 (Pubitemid 34704985)
19. D.J. Sargent, C.H. Khne, and H.K. Sanoff Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer J Clin Oncol 27 2009 1948 1955
20. J. Steinberg, C. Erlichman, and T. Gadalla Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid Eur J Cancer 28A 1992 1817 1820
21. F. Tas, F. Akyan, and S. Alici Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease Am J Clin Oncol 24 2001 547 550 (Pubitemid 33131412)
22. G. Bacci, A. Longhi, and S. Ferrari Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: experience at Rizzoli on 1421 patients treated over the last 30 years Tumori 90 2004 478 484 (Pubitemid 39556797)
23. E. Kondo, M. Ogura, and Y. Kagami Assessment of prognostic factors in follicular lymphoma patients Int J Hematol 73 2001 363 368 (Pubitemid 33758995)
24. M.I. Koukourakis, A. Giatromanolaki, and E. Sivridis Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis Br J Cancer 89 2003 877 885 (Pubitemid 37175811)
25. K. Yuce, C. Baykal, and C. Gen Diagnostic and prognostic value of serum and peritoneal fluid lactate dehydrogenase in epithelial ovarian cancer Eur J Gynaecol Oncol 22 2001 228 232 (Pubitemid 32757877)
26. R.J. Motzer, M. Mazumdar, and J. Bacik Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17 1999 2530 2540 (Pubitemid 29368255)
27. M.I. Koukourakis, M. Pitiakoudis, and A. Giatromanolaki Oxygen and glucose consumption in gastrointestinal adenocarcinomas: correlation with markers of hypoxia, acidity and anaerobic glycolysis Cancer Sci 97 2006 1056 1060 (Pubitemid 44322554)
28. M. Azuma, M. Shi, and K.B. Danenberg Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients Pharmacogenomics 8 2007 1705 1713
29. B. Krishnamachary, S. Berg-Dixon, and B. Kelly Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1 Cancer Res 63 2003 1138 1143 (Pubitemid 36278449)
30. N. Kemeny, and D.W. Braun Jr. Prognostic factors in advanced colorectal carcinoma Importance of lactic dehydrogenase level, performance status, and white blood cell count Am J Med 74 1983 786 794 (Pubitemid 13080121)
31. L. Edler, M.E. Heim, and C. Quintero Prognostic factors of advanced colorectal cancer patients Eur J Cancer Clin Oncol 22 1986 1231 1237 (Pubitemid 17178722)
32. R.T. Chlebowski, I. Silverberg, and T. Pajak Treatment of advanced colon cancer with 5-fluorouracil (NSC19893) versus cyclophosphamide (NSC26271) plus 5-fluorouracil: prognostic aspects of the differential white blood cell count Cancer 45 1980 2240 2244 (Pubitemid 10109108)
33. K.J. Halazun, A. Aldoori, and H.Z. Malik Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases Eur J Surg Oncol 34 2008 55 60 (Pubitemid 350296756)
34. H.Z. Malik, K.R. Prasad, and K.J. Halazun Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases Ann Surg 246 2007 806 814 (Pubitemid 350035657)
35. Y. Kishi, S. Kopetz, and Y.S. Chun Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy Ann Surg Oncol 16 2009 614 622
36. M.O. Ozyurtkan, A.E. Balci, and M. Cakmak Predictors of mortality within three months in the patients with malignant pleural effusion Eur J Intern Med 21 2010 30 34
37. C. Tournigand, T. Andr, and E. Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2004 229 237 (Pubitemid 41095086)
38. E. Van Cutsem, C.H. Khne, and E. Hitre Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
39. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342 (Pubitemid 38702844)